Taysha Gene Therapies Inc

TSHA

Company Profile

  • Business description

    Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

  • Contact

    3000 Pegasus Park Drive
    Suite 1430
    DallasTX75247
    USA

    T: +1 214 612-0000

    https://www.tayshagtx.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    99

Stocks News & Analysis

stocks

ASX gold miner under pressure to sell by activist investor

Activist investor presses gold miner on selling to larger players.
stocks

Ask the Analyst: Will Amcor lose its dividend aristocrat status?

When consistency becomes constraint.
stocks

Chart of the Week: We see opportunity in this beaten down industrial player

The market sees risks and are discounting the shares excessively.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,916.9058.60-0.65%
CAC 408,216.1165.690.81%
DAX 4024,921.29125.350.51%
Dow JONES (US)51,384.26697.191.38%
FTSE 10010,334.472.170.02%
HKSE25,253.40379.81-1.48%
NASDAQ26,691.50162.48-0.61%
Nikkei 22567,470.69931.45-1.36%
NZX 50 Index13,101.6113.47-0.10%
S&P 5007,553.190.49-0.01%
S&P/ASX 2008,686.1059.50-0.68%
SSE Composite Index4,057.7826.19-0.64%

Market Movers